Private Management Group Inc. boosted its holdings in Organon & Co. (NYSE:OGN - Free Report) by 1.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,893,868 shares of the company's stock after purchasing an additional 34,026 shares during the quarter. Organon & Co. accounts for about 1.3% of Private Management Group Inc.'s portfolio, making the stock its 16th largest holding. Private Management Group Inc. owned approximately 0.74% of Organon & Co. worth $36,230,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. LSV Asset Management boosted its stake in shares of Organon & Co. by 47.3% in the second quarter. LSV Asset Management now owns 6,610,768 shares of the company's stock valued at $136,843,000 after buying an additional 2,121,940 shares during the period. Wedge Capital Management L L P NC bought a new position in Organon & Co. in the 2nd quarter valued at about $33,573,000. Kahn Brothers Group Inc. raised its position in Organon & Co. by 3,242.4% during the first quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company's stock valued at $22,188,000 after purchasing an additional 1,144,894 shares in the last quarter. Boston Partners acquired a new position in shares of Organon & Co. during the 1st quarter worth $19,306,000. Finally, AQR Capital Management LLC grew its holdings in shares of Organon & Co. by 39.8% during the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company's stock valued at $71,905,000 after purchasing an additional 988,336 shares during the last quarter. Institutional investors own 77.43% of the company's stock.
Several brokerages have recently issued reports on OGN. Evercore ISI upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a "neutral" rating to an "underweight" rating and upped their price target for the company from $18.00 to $20.00 in a research report on Friday, September 6th.
Read Our Latest Report on Organon & Co.
NYSE:OGN traded down $0.71 on Friday, reaching $18.07. 2,702,952 shares of the stock traded hands, compared to its average volume of 2,182,331. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10. The company's 50 day moving average is $19.38 and its 200-day moving average is $20.10. The firm has a market capitalization of $4.65 billion, a price-to-earnings ratio of 4.65, a price-to-earnings-growth ratio of 0.81 and a beta of 0.84.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.04. The company had revenue of $1.61 billion during the quarter, compared to analysts' expectations of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. Organon & Co.'s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.31 earnings per share. Equities research analysts anticipate that Organon & Co. will post 4.04 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.20%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.'s dividend payout ratio is 28.79%.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.